Tue, Sep 16, 2014, 12:37 PM EDT - U.S. Markets close in 3 hrs 23 mins


% | $
Quotes you view appear here for quick access.

Protalix BioTherapeutics, Inc. (PLX) Message Board

mountainmansmith 4 posts  |  Last Activity: Sep 11, 2014 9:38 AM Member since: Dec 21, 2010
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    conference call

    by slowit Sep 8, 2014 5:52 PM
    mountainmansmith mountainmansmith Sep 11, 2014 9:38 AM Flag

    No incentive for Pfizer to work on Elelyso if they believe it will shortly be replaced by oral drug in which they have no financial interest.
    I also believe PLX is not significantly cutting the price of Elelyso because they don't want to do the same for Fabry drug which will hopefully be more accepted as a biobetter. Keep the prices high. PLX can have the majority of the nearly $1 Billion Fabry market.
    PLX seems well-positioned.
    Hope for good study results.
    Oral Anti-TNF could be blockbuster.
    Cystic Fibrosis Pulmozyme equivalent isn't even on the radar screen yet but could be big.
    Ebola and other licensing agreements possible.
    New Chairman. New CEO search.
    Market cap only 240 million!!
    I like the risk vs. reward.

  • mountainmansmith by mountainmansmith Aug 23, 2014 5:40 PM Flag

    Amazon developing ad software: Report http://www.cnbc.com/id/101942171

  • Reply to

    Question about my call position

    by mister_samosa Aug 22, 2014 11:09 PM
    mountainmansmith mountainmansmith Aug 23, 2014 5:37 PM Flag

    You will need a big move

  • mountainmansmith mountainmansmith Aug 18, 2014 3:47 PM Flag

    Zeev Bronfeld was the interim Chairman of the Board for the past 4 years. That position was given to Shlomo Yanai this past July. Bronfeld remains a member of the board.
    Bronfeld is also the head of Biocell which just sold 4.4 million shares of PLX at 2.47. Biocell still holds over 10 million shares of PLX.
    Why would Biocell sell 4.4 million shares at that price? Maybe raising cash to fund another deal? Shouldn't be based on information about the upcoming trial results because I would think that is considered trading on inside information.
    I watch the trades in this stock closely. I obviously never saw a 4.4 million share block. I never even saw 4.4 million shares trade at 2.47 even in small increments. Was this stock directed to some other entity or simply traded retail? Something is going on and the average shareholder is in the dark. There has been no news released which would explain the recent drop in price into the 2s.
    Aviezer is leaving too.
    New blood with Yanai and a new CEO may be a good thing. They couldn't possibly do a worse job for shareholders!
    Also saw that Yanai is accepting stock options at 3.47 (I think) as part of his compensation. That implies some degree of optimism.
    Lets hope for some good trial results for oral Elelyso which could be a game changer, and for the Fabry biobetter. Other pipeline drugs could move faster too. Maybe Yanai's tie to Teva can help..
    New and hopefully aggressive management seems very favorable to me.

2.46-0.05(-2.03%)12:35 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.